Nebivolol inhibited hepatocellular carcinoma progression by downregulating RHOQ and demonstrated synergistic antitumor effects when combined with lenvatinib.
Does nebivolol inhibit tumor progression and enhance the efficacy of lenvatinib in hepatocellular carcinoma models?
Nebivolol demonstrates potential as a repurposed therapeutic agent for hepatocellular carcinoma by inhibiting tumor progression via RHOQ downregulation and synergizing with lenvatinib.
p-value: p=<0.05
Hepatocellular carcinoma (HCC) is associated with high mortality due to late diagnosis, recurrence, and limited therapeutic options.Thus, there is an urgent need for novel treatment approaches and new therapeutic targets.Cardiotoxicity resulting from anticancer therapies has become increasingly prominent, leading to a higher risk of cardiovascular diseases among cancer survivors.In our study, through a drug library screening, we identified that the cardiovascular therapeutic agent nebivolol exerts antitumor effects against HCC both in vivo and in vitro.Mechanistically, nebivolol suppressed HCC progression by downregulating RHOQ independently of 1-adrenergic receptors.Furthermore, the combination of nebivolol and lenvatinib synergistically inhibited HCC proliferation both in vivo and in vitro.This study provides a rationale for repurposing nebivolol as a combination strategy for HCC therapy.
Zhang et al. (Wed,) conducted a other in Hepatocellular carcinoma (n=211). Nebivolol vs. Vehicle control (DMSO) was evaluated on Tumor volume and weight (p=<0.05). Nebivolol inhibited hepatocellular carcinoma progression by downregulating RHOQ and demonstrated synergistic antitumor effects when combined with lenvatinib.